Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy
Trial ID or NCT#
NCT00349830
Status
RECRUITING
Purpose
The purpose of this study is to measure the levels of serum proteins and other biomarkers in cancer patients and in patients suspected of having cancer. We believe that some of these markers may be useful for confirming the diagnosis or for selecting patients for specific types of cancer therapies. These markers may also help to predict response to therapy, relapse after therapy, and survival after therapy.
Official Title
Development of Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy
Investigator(s)
Maximilian Diehn, MD, PhD
Radiation oncologist
Jack, Lulu, and Sam Willson Professor and Professor of Radiation Oncology (Radiation Therapy)
Billy W Loo Jr, MD PhD FASTRO FACR
Radiation oncologist,
Thoracic specialist
Professor of Radiation Oncology (Radiation Therapy)
Quynh-Thu Le, MD, FACR, FASTRO, FARS
Radiation oncologist
Katharine Dexter McCormick and Stanley McCormick Memorial Professor and Professor, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS)
Anson Lowe
Contact us to find out if this trial is right for you.
Contact
Rene Bonilla
650-498-7703
View on ClinicalTrials.gov
